Search

Displaying results 2071 - 2080 of 6076 in total
  1. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative a...

  2. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940,L64047] It is the second therapy approved for FOP, following [palovarotene] (Sohonos), which was approved in 2023, and is the first FOP therapy shown to reduce clinician-assessed flare-ups.

  3. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

  4. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especi...

    Categories: Antihistamines for Systemic Use
  5. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  6. Drug

    Terizidone

    go.drugbank.com/drugs/DB12954
    ApprovedInvestigationalWithdrawn

    Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  7. Drug

    Dimazole

    go.drugbank.com/drugs/DB13858
    ApprovedWithdrawn

    Dimazole (diamthazole) is an antifungal. It was withdrawn in Franch in 1972 due to neuropsychiatric reactions.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  8. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.[L10896]. … [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.

  9. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose.

  10. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.